Home › Biomarkers › BRAF
BRAF testing: what it means for you
Waiting on test results can feel like one more hard thing, for you and the people who love you. Here's what the BRAF test looks for and how it can help your care team pick the treatment most likely to work for you.
ℹ️ General information to help you and your loved ones talk with your care team, not medical advice. Read our disclaimer.
Matters most in: Lung cancer, Colorectal cancer
The quick guide
What the test looks for: Mutations in the BRAF gene, especially V600E. Common in melanoma and found in a small share of lung and colorectal cancers.
Why it matters
BRAF V600E can be targeted with a combination of a BRAF blocker and another pathway blocker. In colorectal cancer it also tends to mean a more aggressive cancer, so treatment plans account for it.
Treatments it can point to
- Lung: dabrafenib plus trametinib, or encorafenib plus binimetinib
- Colorectal: encorafenib plus an EGFR antibody (cetuximab), sometimes with chemo
Only your care team can say which treatment fits you. Drug approvals depend on cancer type, stage and prior treatment.
Tissue vs. blood testing
Tissue or blood.
Most tests use a piece of tumor tissue from a biopsy or surgery. Some can also use a blood sample (a 'liquid biopsy') that looks for tumor DNA floating in the blood. Blood tests are easier and faster, but they can miss a change that a tissue test would find, so a negative blood test is often followed by a tissue test.
❓ Questions you and your loved ones can ask
- Do I have the V600E change or a different BRAF change?
- When will my results be back, and will treatment wait for them?
- Will my insurance cover this test?
Written by the Cancer Side Effects Guide team from FDA labels and leading cancer centers. Not medical advice. · Last updated: October 15, 2026 · How we write
Sources
- NCI: Targeted Therapy to Treat Cancer
- Memorial Sloan Kettering: Targeted Therapy & Precision Oncology
- NCI: Biomarker Testing for Cancer Treatment
- FDA: List of Cleared or Approved Companion Diagnostic Devices
- NCCN Guidelines for Patients: Early and Locally Advanced Non-Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Colon Cancer, 2026
- NCCN Guidelines for Patients: Rectal Cancer, 2026